JAAN BIOTHERAPEUTICS LLC
AAV gene therapy vector (JBT-miR2) that inhibits four microRNAs to promote cardiomyocyte regeneration after myocardial infarction
- Sector
- Biotech
- Headquarters
- La Jolla, CA
- Total capital
- $2.7M
- Federal grants
- $2.7M
- 7 awards · 2017–2025
- Rank in peer group#148 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 13 pending · first 2021
- Rank in peer group#28 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Heart Muscle Regeneration$1.3M
- Federal grantHealth and Human S · Phase I · Viral Delivered Cardiac Regeneration$52K
- Federal grantHealth and Human S · Phase I · Viral Delivered Cardiac Regeneration$373K
- Federal grantHealth and Human S · Phase I · Viral Delivered Cardiac Regeneration$321K
- Federal grantHealth and Human S · Phase I · MicroRNA Inhibition for Cardiac Regeneration in Ischemia$241K
- Federal grantHealth and Human S · Phase I · MicroRNA Inhibition for Cardiac Regeneration in Ischemia$241K
- Federal grantHealth and Human S · Phase I · Oligonucleotide Inhibition for cardiac regeneration in Ischemia$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#148 · top 29%
- Granted patents#28 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 3 granted of 16- PendingMicrorna Targeting Regenerative Treatments For Heart FailureUSPTOApplication 18807909
- PendingCompositions And Methods For Treatment Of Cardiac DiseasesUSPTOApplication 18160998
- GrantedCompositions And Methods For Treatment Of Cardiac DiseasesUSPTOUS 11,566,243
Show all 16 patent records
- Microrna Targeting Regenerative Treatments For Heart FailureDec 12, 2024 · Application 18807909Pending
- Compositions And Methods For Treatment Of Cardiac DiseasesFeb 29, 2024 · Application 18160998Pending
- Compositions And Methods For Treatment Of Cardiac DiseasesJan 31, 2023 · US 11,566,243Granted
- Compositions And Methods For Mitigation Of Ischemic Reperfusion InjurySep 29, 2022 · Application 17770031Pending
- Compositions And Methods For Treatment Of Cardiac DiseasesAug 23, 2022 · US 11,421,232Granted
- Compositions And Methods For Treatment Of Cardiac DiseasesSep 21, 2021 · US 11,124,793Granted
- Therapeutics That Regenerate Heart Muscle By Targeting Specific MicrornasApplication 62937429Pending
- Therapeutics That Regenerate Heart Muscle By Targeting Specific MicrornasApplication 62923612Pending
- Compositions And Methods For Treatment Of Cardiac DiseasesApplication PCTUS2017042400Pending
- Compositions And Methods For Treatment Of Muscular DystrophyApplication 62419852Pending
- Compositions And Methods For Inhibiting Micrornas MIR-99A-5P, MIR-100-5P, LET-7A-5P, And LET-7C-5PApplication 62363512Pending
- Microrna Targeting Regenerative Treatments For Heart FailureApplication PCTUS2023062775Pending
- Microrna Targeting Regenerative Treatments For Heart FailureApplication 63311448Pending
- Compositions And Methods For Mitigation Of Ischemic Reperfusion InjuryApplication PCTUS2020056536Pending
- Use of MiRNA Inhibitors to Mitigate Cardiac Ischemic Reperfusion InjuryApplication 62981531Pending
- Systemic Single Administration of MiRNA Inhibitors Mitigates Cardiac Ischemic Reperfusion Injury in the MouseApplication 62961418Pending
Related companies, and why
- Pelthos Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Mediar TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Monte Rosa Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Tyra Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- SIEGE PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- Third Harmonic BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .